Clinical Trials

FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). The Phase 1/2 LuMIERE study of FAP-2286 sponsored by 3BP’s partner Clovis Oncology is enrolling. 3BP holds the rights for Europe (inclusive of Russia, Turkey, and Israel) whereas Clovis Oncology holds US and global rights excluding Europe, Russia, Turkey, and Israel. FAP-2286 is an unlicensed medical product. More information about FAP-2286 and Targeted Radionuclide Therapy (TRT) is available from targetedradiotherapy.com (Clovis Oncology).

Study of ¹⁷⁷Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

Summary: Phase 1 of this study will evaluate the safety and tolerability of ¹⁷⁷Lu-FAP-2286 and determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Phase 2 of this study is designed to evaluate objective response rate (ORR) in patients with specific solid tumors.

Study Status: Enrolling

Study Identifier: NCT04939610

Imaging of Solid Tumors Using ⁶⁸Ga-FAP-2286

Summary: This is a single arm prospective trial that evaluates the ability of a novel imaging agent gallium-68 labelled (⁶⁸Ga-) FAP-2286 (⁶⁸Ga-FAP-2286) to detect metastatic cancer in participants with solid tumors.

Study Status: Enrolling

Study Identifier: NCT04621435

Imaging of Pathologic Fibrosis Using ⁶⁸Ga-FAP-2286

Summary: This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (⁶⁸Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis.

Study Status: Enrolling

Study Identifier: NCT05180162